Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial - Tim W. Harrison, Pascal Chanez, Francesco Menzella, Giorgio Walter Canonica, Renaud Louis, Borja G. Cosio, Njira L. Lugogo, Arjun Mohan, Annie Burden, Lawrence McDermott, Esther Garcia Gil, James G. Zangrilli, Wolfgang Pohl, Robert Voves, Maud Deschampheleire - Dissemin

Language
Login

Published in

Elsevier, The Lancet Respiratory Medicine, 3(9), p. 260-274, 2021

DOI: 10.1016/s2213-2600(20)30414-8

Links

Elsevier

Tools

Export citation

Search in Google Scholar

Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial

Journal article published in 2020 by Tim W. Harrison, Pascal Chanez, Francesco Menzella, Giorgio Walter Canonica, Renaud Louis, Borja G. Cosio, Njira L. Lugogo, Arjun Mohan, Annie Burden, Lawrence McDermott, Esther Garcia Gil, James G. Zangrilli, Wolfgang Pohl, Robert Voves, Maud Deschampheleire and other authors.

This paper was not found in any repository, but could be made available legally by the author.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle

Preprint: archiving allowed

Upload

Green circle

Postprint: archiving allowed

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO